Comparative Pharmacology
Head-to-head clinical analysis: PAZOPANIB HYDROCHLORIDE versus PEMAZYRE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PAZOPANIB HYDROCHLORIDE versus PEMAZYRE.
PAZOPANIB HYDROCHLORIDE vs PEMAZYRE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pazopanib is a multi-targeted tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptors (VEGFR-1, -2, -3), platelet-derived growth factor receptors (PDGFR-α, -β), and stem cell factor receptor (c-Kit). It also inhibits other kinases such as fibroblast growth factor receptors (FGFR-1, -3), cytokine receptor (Kit), interleukin-2 receptor inducible T-cell kinase (Itk), leukocyte-specific protein tyrosine kinase (Lck), and transmembrane glycoprotein receptor (c-Fms).
Selective inhibitor of fibroblast growth factor receptor (FGFR) 1, 2, 3, and 4; binds to and inhibits FGFR kinase activity, leading to decreased tumor cell proliferation and angiogenesis.
800 mg orally once daily without food (at least 1 hour before or 2 hours after a meal). Do not crush tablets.
13.5 mg orally once daily continuously until disease progression or unacceptable toxicity.
None Documented
None Documented
Terminal half-life is approximately 31 hours, supporting once-daily dosing.
Terminal elimination half-life is approximately 20 hours (range 14–32 h), supporting once-daily dosing with steady-state reached within 8 days.
Primarily fecal (83%), with renal elimination accounting for <4% of the administered dose.
Primarily hepatobiliary excretion: 72% of the dose recovered in feces (mainly as unchanged drug and metabolites); renal excretion accounts for approximately 17% (less than 1% unchanged).
Category D/X
Category C
Kinase Inhibitor
Kinase Inhibitor